Leerink Partnrs Has Negative View of BeiGene FY2025 Earnings

BeiGene, Ltd. (NASDAQ:BGNE) – Equities researchers at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of BeiGene in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of $0.73 for the year, down from their prior forecast of $0.79. The consensus estimate for BeiGene’s current full-year earnings is ($5.00) per share. Leerink Partnrs also issued estimates for BeiGene’s FY2026 earnings at $8.11 EPS and FY2027 earnings at $13.54 EPS.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.15%. BeiGene’s revenue was up 28.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.01 EPS.

Several other brokerages also recently commented on BGNE. JMP Securities started coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target on the stock. JPMorgan Chase & Co. raised their price target on shares of BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 22nd. Citigroup upped their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. TD Cowen boosted their price target on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, StockNews.com upgraded BeiGene from a “hold” rating to a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $247.07.

BeiGene Stock Up 0.9 %

BGNE stock opened at $195.45 on Thursday. BeiGene has a 52-week low of $126.97 and a 52-week high of $248.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. The stock has a market capitalization of $19.04 billion, a price-to-earnings ratio of -23.72 and a beta of 0.63. The company has a 50-day moving average of $212.91 and a two-hundred day moving average of $181.72.

Insider Activity

In other BeiGene news, insider Titus B. Ball sold 137 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total transaction of $26,021.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Chan Henry Lee sold 1,202 shares of the firm’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $237.10, for a total value of $284,994.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total transaction of $26,021.78. The disclosure for this sale can be found here. Insiders have sold 23,070 shares of company stock valued at $4,901,050 over the last 90 days. 7.43% of the stock is owned by company insiders.

Institutional Trading of BeiGene

A number of hedge funds have recently made changes to their positions in the business. FMR LLC increased its stake in shares of BeiGene by 0.8% during the third quarter. FMR LLC now owns 1,660,011 shares of the company’s stock worth $372,689,000 after purchasing an additional 12,855 shares during the period. The Manufacturers Life Insurance Company raised its stake in BeiGene by 14.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 57,384 shares of the company’s stock worth $12,883,000 after purchasing an additional 7,122 shares in the last quarter. DRW Securities LLC bought a new stake in BeiGene in the 3rd quarter valued at about $573,000. Citigroup Inc. lifted its position in shares of BeiGene by 25.9% during the 3rd quarter. Citigroup Inc. now owns 26,312 shares of the company’s stock valued at $5,907,000 after acquiring an additional 5,410 shares during the period. Finally, Massachusetts Financial Services Co. MA bought a new position in BeiGene in the 3rd quarter valued at about $2,666,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.